SinoMab BioScience HKSE IPO

12/11/2019
IPO

HK$ 1.75 billion

Completed

12/11/2019


Overview:

  • Hong Kong-based biopharmacuetical company SinoMab BioScience has made a $223 million global offering and IPO on Hong Kong's stock exchange.
  • SinoMab BioScience is dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases, primarily in monoclonal antibody-based biologics. 

Adam Majeed - Asia editor

Continue reading...

New to IFLR1000?

Register today for FREE:

  • Understand market dynamics, with data broken by deal type and more
  • Access law firms and lawyers involved in deals
  • Gain unique insight into lawyers recent work
REGISTER NOW

Sign in